1. Home
  2. List
Reference Patent

Reference - List

  • 18 Hits
  • Search Condition : Filter (MeSH = Protein Kinase Inhibitors / administration & dosage)
Species Resource Title
Human and Animal Cells KP4(RCB1005) LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Human and Animal Cells NUGC-4(RCB1939) The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
Human and Animal Cells T98G(RCB1954) Targeting JNK for therapeutic depletion of stem-like glioblastoma cells.
Human and Animal Cells Lu99(RCB1900) Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Human and Animal Cells Ba/F3 Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Human and Animal Cells Ba/F3 Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Human and Animal Cells KP4(RCB1005) Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Human and Animal Cells Ba/F3(RCB0805) , LC-2/ad(RCB0440) Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Human and Animal Cells WI-38(RCB0702) , A549(RCB0098) Assessment of transporter-mediated efflux of nintedanib using in vitro cell line models of idiopathic pulmonary fibrosis.
Human and Animal Cells ACC-MESO-1(RCB2292) , II-18(RCB2093) Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Human and Animal Cells OCUB-M(RCB0881) Development of a potent and orally active activator of adenosine monophosphate-activated protein kinase (AMPK), ASP4132, as a clinical candidate for the treatment of human cancer.
Human and Animal Cells StromaNKtert(RCB2350) Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
DNA material phRIT2 (RDB16941) , CSII-CMV-MCS-IRES2-Venus (RDB04383) , pCAG-HIVgp (RDB04394) , pCMV-VSV-G-RSV-Rev (RDB04393) In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease.
Human and Animal Cells LC-2/ad(RCB0440) , PC-9(RCB4455) , A549(RCB0098) , RERF-LCKJ(RCB1313) AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
Pathogenic microorganisms IFM 53637 Inhalation of Stachybotrys chartarum evokes pulmonary arterial remodeling in mice, attenuated by Rho-kinase inhibitor.
Human and Animal Cells TKKK(RCB1907) Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Human and Animal Cells ACC-MESO-1(RCB2292) , ACC-MESO-4(RCB2293) Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Human and Animal Cells KU812(RCB0495) , K562 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.